Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Tremblay

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Pharmacoeconomics|August 9, 2021
Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON TrialMichael Dolph, Gabriel Tremblay, Hoyee Leong
Clinicoeconomics and Outcomes Research : CEOR|June 18, 2021
US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple MyelomaMike Dolph, Gabriel Tremblay, Hoyee Leong
Journal of Health Economics and Outcomes Research|September 4, 2023
A Criterion-based Approach for the Systematic and Transparent Extrapolation of Clinical Trial Survival DataGabriel Tremblay, Patrick Haines, Andrew Briggs
Journal of Health Economics and Outcomes Research|March 26, 2021
Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment ComparisonsGabriel Tremblay, Dimitrios Tomaras, Eric Strati, et al.
Journal of Health Economics and Outcomes Research|October 7, 2021
Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple MyelomaMichael Dolph, Gabriel Tremblay, Adrienne M Gilligan, et al.
Journal of Health Economics and Outcomes Research|September 4, 2023
Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of TherapyGabriel Tremblay, Unnati Majethia, Ilias Kontoudis, et al.
Journal of Medical Economics|March 25, 2015
Costing bias in economic evaluationsJulie Frappier, Gabriel Tremblay, Mark Charny, et al.
Clinicoeconomics and Outcomes Research : CEOR|July 16, 2016
Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancerGabriel Tremblay, Christopher Livings, Lydia Crowe, et al.
Cost Effectiveness and Resource Allocation : C/E|October 17, 2018
Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United KingdomGabriel Tremblay, Mike Dolph, Sachin Patel, et al.
Journal of Comparative Effectiveness Research|November 28, 2019
A criterion-based approach to systematic and transparent comparative effectiveness: a case study in psoriatic arthritisGabriel Tremblay, Tracy Westley, Anna Forsythe, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Pharmacoeconomics|August 9, 2021
Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON TrialMichael Dolph, Gabriel Tremblay, Hoyee Leong
Clinicoeconomics and Outcomes Research : CEOR|June 18, 2021
US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple MyelomaMike Dolph, Gabriel Tremblay, Hoyee Leong
Journal of Health Economics and Outcomes Research|September 4, 2023
A Criterion-based Approach for the Systematic and Transparent Extrapolation of Clinical Trial Survival DataGabriel Tremblay, Patrick Haines, Andrew Briggs
Journal of Health Economics and Outcomes Research|March 26, 2021
Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment ComparisonsGabriel Tremblay, Dimitrios Tomaras, Eric Strati, et al.
Journal of Health Economics and Outcomes Research|October 7, 2021
Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple MyelomaMichael Dolph, Gabriel Tremblay, Adrienne M Gilligan, et al.
Journal of Health Economics and Outcomes Research|September 4, 2023
Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of TherapyGabriel Tremblay, Unnati Majethia, Ilias Kontoudis, et al.
Journal of Medical Economics|March 25, 2015
Costing bias in economic evaluationsJulie Frappier, Gabriel Tremblay, Mark Charny, et al.
Clinicoeconomics and Outcomes Research : CEOR|July 16, 2016
Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancerGabriel Tremblay, Christopher Livings, Lydia Crowe, et al.
Cost Effectiveness and Resource Allocation : C/E|October 17, 2018
Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United KingdomGabriel Tremblay, Mike Dolph, Sachin Patel, et al.
Journal of Comparative Effectiveness Research|November 28, 2019
A criterion-based approach to systematic and transparent comparative effectiveness: a case study in psoriatic arthritisGabriel Tremblay, Tracy Westley, Anna Forsythe, et al.
Pageof 6